ARCHIVES

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

This article is from The Cancer Letter archive.

Vol. 23 No. 32 | August 15, 1997

Download PDF Visit The Full Archive

Related Articles

Blinatumomab Demonstrates High Response Rate in ALL

June 29, 2012

Clearinghouse Says In Business

January 26, 1979

FDA Approves Arranon For Leukemia And Lymphoma

December 30, 2005

Minority Trial Participation A Matter of Access, Study Says

December 30, 2005

Surprise Finding On HRT Stops Large Trial, Women Advised To Reconsider Long-Term Use Due to Increased Breast Cancer Risk

July 12, 2002

This month’s 8-page Business & Regulatory Report included in this issue.

January 30, 2004